IBDEI0AM ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4444,1,4,0)
 ;;=4^Z76.0
 ;;^UTILITY(U,$J,358.3,4444,2)
 ;;=^5063297
 ;;^UTILITY(U,$J,358.3,4445,0)
 ;;=Z04.8^^30^277^16
 ;;^UTILITY(U,$J,358.3,4445,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4445,1,3,0)
 ;;=3^Examination/Observation for Other Reasons
 ;;^UTILITY(U,$J,358.3,4445,1,4,0)
 ;;=4^Z04.8
 ;;^UTILITY(U,$J,358.3,4445,2)
 ;;=^5062665
 ;;^UTILITY(U,$J,358.3,4446,0)
 ;;=N39.0^^30^277^36
 ;;^UTILITY(U,$J,358.3,4446,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4446,1,3,0)
 ;;=3^UTI
 ;;^UTILITY(U,$J,358.3,4446,1,4,0)
 ;;=4^N39.0
 ;;^UTILITY(U,$J,358.3,4446,2)
 ;;=^124436
 ;;^UTILITY(U,$J,358.3,4447,0)
 ;;=B19.20^^30^277^22
 ;;^UTILITY(U,$J,358.3,4447,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4447,1,3,0)
 ;;=3^Hepatitis C,Viral
 ;;^UTILITY(U,$J,358.3,4447,1,4,0)
 ;;=4^B19.20
 ;;^UTILITY(U,$J,358.3,4447,2)
 ;;=^331436
 ;;^UTILITY(U,$J,358.3,4448,0)
 ;;=B20.^^30^277^19
 ;;^UTILITY(U,$J,358.3,4448,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4448,1,3,0)
 ;;=3^HIV
 ;;^UTILITY(U,$J,358.3,4448,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,4448,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,4449,0)
 ;;=G35.^^30^277^31
 ;;^UTILITY(U,$J,358.3,4449,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4449,1,3,0)
 ;;=3^Multiple Sclerosis
 ;;^UTILITY(U,$J,358.3,4449,1,4,0)
 ;;=4^G35.
 ;;^UTILITY(U,$J,358.3,4449,2)
 ;;=^79761
 ;;^UTILITY(U,$J,358.3,4450,0)
 ;;=D68.311^^30^277^21
 ;;^UTILITY(U,$J,358.3,4450,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4450,1,3,0)
 ;;=3^Hemophilia,Acquired
 ;;^UTILITY(U,$J,358.3,4450,1,4,0)
 ;;=4^D68.311
 ;;^UTILITY(U,$J,358.3,4450,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,4451,0)
 ;;=D68.312^^30^277^10
 ;;^UTILITY(U,$J,358.3,4451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4451,1,3,0)
 ;;=3^Antiphospholipid Antibody w/ Hemorrhagic Disorder
 ;;^UTILITY(U,$J,358.3,4451,1,4,0)
 ;;=4^D68.312
 ;;^UTILITY(U,$J,358.3,4451,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,4452,0)
 ;;=Z51.81^^30^277^35
 ;;^UTILITY(U,$J,358.3,4452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4452,1,3,0)
 ;;=3^Therapeutic Drug Level Monitoring
 ;;^UTILITY(U,$J,358.3,4452,1,4,0)
 ;;=4^Z51.81
 ;;^UTILITY(U,$J,358.3,4452,2)
 ;;=^5063064
 ;;^UTILITY(U,$J,358.3,4453,0)
 ;;=L03.90^^30^277^11
 ;;^UTILITY(U,$J,358.3,4453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4453,1,3,0)
 ;;=3^Cellulitis,Unspec
 ;;^UTILITY(U,$J,358.3,4453,1,4,0)
 ;;=4^L03.90
 ;;^UTILITY(U,$J,358.3,4453,2)
 ;;=^5009067
 ;;^UTILITY(U,$J,358.3,4454,0)
 ;;=99456^^31^278^2
 ;;^UTILITY(U,$J,358.3,4454,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4454,1,1,0)
 ;;=1^C&P F-T-F Visit
 ;;^UTILITY(U,$J,358.3,4454,1,2,0)
 ;;=2^99456
 ;;^UTILITY(U,$J,358.3,4455,0)
 ;;=99456^^31^278^4
 ;;^UTILITY(U,$J,358.3,4455,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4455,1,1,0)
 ;;=1^C&P Telehealth Visit
 ;;^UTILITY(U,$J,358.3,4455,1,2,0)
 ;;=2^99456
 ;;^UTILITY(U,$J,358.3,4456,0)
 ;;=99241^^31^278^5
 ;;^UTILITY(U,$J,358.3,4456,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4456,1,1,0)
 ;;=1^C&P ACE Chart Review
 ;;^UTILITY(U,$J,358.3,4456,1,2,0)
 ;;=2^99241
 ;;^UTILITY(U,$J,358.3,4457,0)
 ;;=99456^^31^278^6
 ;;^UTILITY(U,$J,358.3,4457,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4457,1,1,0)
 ;;=1^IDES F-T-F Visit
 ;;^UTILITY(U,$J,358.3,4457,1,2,0)
 ;;=2^99456
 ;;^UTILITY(U,$J,358.3,4458,0)
 ;;=99456^^31^278^7
 ;;^UTILITY(U,$J,358.3,4458,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4458,1,1,0)
 ;;=1^IDES Telehealth Visit
 ;;^UTILITY(U,$J,358.3,4458,1,2,0)
 ;;=2^99456
 ;;^UTILITY(U,$J,358.3,4459,0)
 ;;=99456^^31^279^1
 ;;^UTILITY(U,$J,358.3,4459,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,4459,1,1,0)
 ;;=1^C&P F-T-F Visit
